LUM and familial pancreatic carcinoma: Given the low efficacy of chemotherapeutics against pancreatic cancer, data revealing potent cytotoxicity in PDAC via lumican and gemcitabine co-treatment posit lumican as a promising ECM-derived protein therapy to sensitize cancer cells to chemotherapeutics.